Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2019 to Jul 2024
Bruker AXS Inc. today announces the promotions of Dr.
Frank Burgaezy, Roger Durst, Ph.D. and Bernard Kolodziej to Executive
Vice Presidents. The newly appointed Bruker AXS executive management
team will be responsible for leading all aspects of the Bruker AXS
business, including global sales and marketing, customer support,
manufacturing, research and development, operations and financial
management.
Executive Vice President Dr. Frank Burgaezy now leads the Bruker
AXS X-ray diffraction (XRD) business as well as its X-ray fluorescence
(XRF) business, and also has global responsibility for marketing at
Bruker AXS. Frank is based in Karlsruhe, Germany, and has been the
global XRD business manager since September 2002. From 1990 to 2002,
Dr. Burgaezy held several scientific, product management and other
management positions at Siemens AXS and later Bruker AXS. He studied
physics at the University of Stuttgart and at Oregon State University,
and he earned his doctorate in physics at the Max-Planck Institute in
Stuttgart, Germany.
Executive Vice President Roger Durst, Ph.D., now leads the Bruker
AXS X-ray single crystal diffraction (SCD) business, and as Chief
Technology Officer heads global R&D. Roger is based in Madison,
Wisconsin, and previously has managed the same functions as Vice
President. Dr. Durst joined Siemens AXS in 1996 as a development
scientist and has held several scientific and management positions at
Bruker AXS. He received his S.B. in aeronautics and astronautics from
the Massachusetts Institute of Technology and his Ph.D. in physics
from the University of Texas at Austin.
Executive Vice President Bernard Kolodziej now leads the global
finance function and European operations, as well as many of the
worldwide subsidiaries of Bruker AXS. Bernard is based in Karlsruhe,
Germany, and has been Vice President of Finance since April 2004.
Previously, Mr. Kolodziej was CFO of European operations since January
1999. Between 1995 and 1999, he held several operations and financial
positions within Siemens AXS and later Bruker AXS. Mr. Kolodziej has a
Master's degree in business administration, finance and production
engineering from the University of Karlsruhe, Germany.
Frank Laukien, President and CEO of Bruker BioSciences, said: "We
are fortunate to have this team of seasoned and successful executives
provide continued and expanded leadership to Bruker AXS. Each of the
new Executive Vice Presidents has an outstanding record of
accomplishment. I am confident that, together with our established
senior management team, they will continue to drive Bruker AXS' growth
and financial performance through innovation, successful product
development and responsive customer support, as well as operational
excellence and margin improvements."
ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)
Bruker BioSciences Corporation, headquartered in Billerica,
Massachusetts, is the publicly traded parent company of Bruker
Daltonics Inc. and Bruker AXS Inc. Bruker AXS is a leading developer
and provider of life science and advanced materials research tools
based on x-ray technology. Bruker Daltonics is a leading developer and
provider of innovative life science tools based on mass spectrometry.
Bruker Daltonics also offers a broad line of nuclear, biological and
chemical (NBC) detection products for defense and homeland security.
For more information, please visit www.bruker-biosciences.com.
CAUTIONARY STATEMENT
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements as
that term is defined in the Private Securities Litigation Reform Act
of 1995. Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results to
differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
reorganization strategies, integration risks, failure of conditions,
technological approaches, product development, market acceptance, cost
and pricing of the Company's products, exposure to currency
fluctuations, changes in governmental regulations, capital spending
and government funding policies, FDA and other regulatory approvals to
the extent applicable, competition, the intellectual property of
others, patent protection and litigation. These and other factors are
identified and described in more detail in our filings with the SEC,
including, without limitation, our respective annual reports on Form
10-K for the year ended December 31, 2004, our most recent quarterly
reports on Form 10-Q, and our current reports on Form 8-K. We disclaim
any intent or obligation to update these forward-looking statements.